- Home
- CRDF vs MTLS Comparison
CRDF vs MTLS Comparison
Compare CRDF & MTLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- MTLS
- Stock Information
- Founded
- CRDF 1999
- MTLS 1990
- Country
- CRDF United States
- MTLS Belgium
- Employees
- CRDF N/A
- MTLS N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- MTLS Computer Software: Prepackaged Software
- Sector
- CRDF Health Care
- MTLS Technology
- Exchange
- CRDF Nasdaq
- MTLS Nasdaq
- Market Cap
- CRDF 288.7M
- MTLS 297.1M
- IPO Year
- CRDF N/A
- MTLS 2014
- Fundamental
- Price
- CRDF $3.83
- MTLS $5.09
- Analyst Decision
- CRDF Strong Buy
- MTLS Buy
- Analyst Count
- CRDF 4
- MTLS 1
- Target Price
- CRDF $12.00
- MTLS $9.50
- AVG Volume (30 Days)
- CRDF 1.1M
- MTLS 497.1K
- Earning Date
- CRDF 05-01-2025
- MTLS 04-24-2025
- Dividend Yield
- CRDF N/A
- MTLS N/A
- EPS Growth
- CRDF N/A
- MTLS 106.79
- EPS
- CRDF N/A
- MTLS 0.24
- Revenue
- CRDF $683,000.00
- MTLS $276,182,835.00
- Revenue This Year
- CRDF N/A
- MTLS $6.55
- Revenue Next Year
- CRDF N/A
- MTLS $9.21
- P/E Ratio
- CRDF N/A
- MTLS $22.46
- Revenue Growth
- CRDF 39.96
- MTLS 4.15
- 52 Week Low
- CRDF $2.01
- MTLS $4.70
- 52 Week High
- CRDF $6.42
- MTLS $9.69
- Technical
- Relative Strength Index (RSI)
- CRDF 43.91
- MTLS 33.95
- Support Level
- CRDF $3.52
- MTLS $5.15
- Resistance Level
- CRDF $4.42
- MTLS $5.46
- Average True Range (ATR)
- CRDF 0.29
- MTLS 0.18
- MACD
- CRDF -0.04
- MTLS 0.11
- Stochastic Oscillator
- CRDF 18.89
- MTLS 37.29
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").
About MTLS Materialise NV
Materialise NV is a provider of 3D printing services. The products and services of the group are organized in three segments: Medical segment, which develops and delivers medical software solutions, medical devices, and other related products and services; Software segment, which develops and delivers additive manufacturing software solutions and related services; and Manufacturing segment, which delivers 3D printed products and related services. Its geographical segments are the United States, the Americas (excluding the USA), Belgium, Germany, Poland, France, Switzerland, the United Kingdom, Italy, the Netherlands, Other Europe, and the Asia Pacific.